Once daily fluticasone propionate at 250 µg produces improvement in pulmonary function and asthma symptom control in patients with asthma.
“This new treatment regimen provides clinicians with an additional therapeutic option for patients with asthma previously treated with either beta2-agonists alone or inhaled corticosteroids,” write researchers led by Dr. William Berger of the University of California at Irvine, in Irvine, California, United States.
They evaluated the efficacy of inhaled fluticasone propionate in 408 patients receiving a short-acting beta agonist and in 401 patients using inhaled corticosteroids. Participants were randomised to either fluticasone 250 µg or placebo each morning for 12 weeks.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!